OrbiMed Advisors

OrbiMed Advisors
Name	OrbiMed Advisors
Type	Private
Industry	Asset management
Founded	1989
Founders	Samuel Isaly
Headquarters	New York City
Key people	Joseph Edelman, Annie Lamont, Barbara Weber
Products	Healthcare investment funds, private equity, venture capital
Assets	US$18.5 billion (estimate)

OrbiMed Advisors

OrbiMed Advisors is a global investment firm specializing in healthcare and life sciences investing with roots in New York City, Boston, and San Francisco. The firm operates across public and private markets, providing venture capital, growth equity, and hedge fund strategies to institutional investors, family offices, and high-net-worth individuals. OrbiMed's activities intersect with major pharmaceutical companies, biotechnology startups, and medical device manufacturers as it competes with other asset managers and specialized investors.

History

OrbiMed emerged in the late 20th century amid a wave of healthcare-focused investing that involved actors like Goldman Sachs, Morgan Stanley, JP Morgan, BlackRock, and State Street Corporation. Its founding coincided with regulatory and scientific milestones involving Food and Drug Administration, National Institutes of Health, Harvard University, Stanford University, and Massachusetts Institute of Technology. Early years saw interactions with corporate transactions involving Pfizer, Merck & Co., Johnson & Johnson, GlaxoSmithKline, and Eli Lilly and Company. The firm expanded during eras shaped by events such as the Dot-com bubble aftermath, the 2008 financial crisis, and later periods influenced by breakthroughs at institutions like Broad Institute, Salk Institute, and Cold Spring Harbor Laboratory. Strategic hires and fund launches connected OrbiMed to networks that include Sequoia Capital, Kleiner Perkins, New Enterprise Associates, Bessemer Venture Partners, and Flagship Pioneering.

Business Model and Investment Strategy

OrbiMed employs a multi-strategy model combining public equity, private equity, venture capital, and credit strategies similar to peers such as TPG, Kohlberg Kravis Roberts, Blackstone Group, Carlyle Group, and Bain Capital. The firm emphasizes sector expertise across biotechnology, pharmaceuticals, medical devices, diagnostics, and healthcare services, engaging with regulatory pathways involving European Medicines Agency, U.S. Securities and Exchange Commission, and intellectual property frameworks like those overseen by the United States Patent and Trademark Office. Investment decisions often rely on scientific collaborations with researchers from Johns Hopkins University, University of California, San Francisco, Columbia University, Yale University, and University of Pennsylvania. OrbiMed conducts due diligence that reflects interactions with contract research organizations such as IQVIA and Charles River Laboratories and supply-chain partners including Thermo Fisher Scientific and Danaher Corporation.

Portfolio and Notable Investments

OrbiMed's portfolio has included public stakes and private financings in companies spanning from early-stage biotech to established pharmaceutical firms. Notable investments and relationships overlap with companies and entities like Amgen, Gilead Sciences, Regeneron Pharmaceuticals, Moderna, Vertex Pharmaceuticals, Illumina, CRISPR Therapeutics, Editas Medicine, Biogen, Alnylam Pharmaceuticals, Bluebird Bio, Sarepta Therapeutics, Guardant Health, Intuitive Surgical, Boston Scientific, Medtronic, Abbott Laboratories, AbbVie, Roche, Novartis, AstraZeneca, Takeda Pharmaceutical Company, Bristol-Myers Squibb, Sanofi, Alector, Denali Therapeutics, Pandion Therapeutics, BridgeBio Pharma, Sana Biotechnology, Beam Therapeutics, Voyager Therapeutics, Spark Therapeutics, Nektar Therapeutics, Esperion Therapeutics, Alcon, Hemlibra, Genentech, Celgene, Actelion, Alexion Pharmaceuticals, Mallinckrodt, Catalent, WuXi AppTec, Loxo Oncology, Incyte Corporation, Ariad Pharmaceuticals, Xencor and Allogene Therapeutics. The firm has participated in IPO transactions on exchanges such as New York Stock Exchange and NASDAQ and in private rounds alongside investors like Index Ventures, Accel Partners, OrbiMed Partners (note: internal fund names), and Bain Capital Ventures.

Organizational Structure and Leadership

OrbiMed's leadership has included senior investment professionals with backgrounds at institutions such as Goldman Sachs, Morgan Stanley, Lehman Brothers, Barclays, UBS, and academic affiliations with Columbia Business School, Harvard Business School, Wharton School, Yale School of Medicine, and Harvard Medical School. The firm's governance involves partner-led investment committees and compliance functions that interact with regulators including the U.S. Department of Justice and the Securities and Exchange Commission. Offices and regional leadership teams operate in global financial centers like New York City, San Francisco, London, Hong Kong, Mumbai, and Tel Aviv, working with local investors such as Temasek Holdings, SoftBank, GIC, Blackstone, and KKR.

Financial Performance and Assets Under Management

OrbiMed manages multi-billion dollar pools of capital with assets under management figures reported in the billions and periodic fundraising activities resembling those of Sequoia Capital, NEA, TPG, Apollo Global Management, and CVC Capital Partners. Performance metrics include returns derived from realized exits through mergers and acquisitions involving buyers like Johnson & Johnson, Roche, Pfizer, Bristol-Myers Squibb, and through public markets via listings on NASDAQ and NYSE. The firm’s funds attract limited partners such as CalPERS, Harvard Management Company, Yale Investments Office, Princeton University Investment Company, Ontario Teachers' Pension Plan, Abu Dhabi Investment Authority, Qatar Investment Authority, and large family offices.

Controversies and Legal Issues

OrbiMed has faced controversies and legal scrutiny similar to other major investors; such matters have involved governance disputes, regulatory investigations, and personnel-related issues comparable to high-profile cases involving firms like Citigroup, Deutsche Bank, UBS, Credit Suisse, HSBC, Goldman Sachs, and Morgan Stanley. Media coverage and litigation have referenced interactions with stakeholders in transactions that included Valeant Pharmaceuticals International, Theranos, Martin Shkreli-era controversies, and contested board dynamics resembling disputes at Aveo Pharmaceuticals and Sarepta Therapeutics. The firm has navigated compliance and settlement environments overseen by agencies such as the Securities and Exchange Commission and courts in jurisdictions like New York Supreme Court and United States District Court for the Southern District of New York.

Category:Investment management companies Category:Financial services companies of the United States